Katja Ott

Summary

Affiliation: Klinikum rechts der Isar
Country: Germany

Publications

  1. ncbi request reprint Prediction of response to preoperative chemotherapy in gastric carcinoma by metabolic imaging: results of a prospective trial
    Katja Ott
    Department of Surgery, Technische Universitä München, Munich, Germany
    J Clin Oncol 21:4604-10. 2003
  2. ncbi request reprint Metabolic imaging predicts response, survival, and recurrence in adenocarcinomas of the esophagogastric junction
    Katja Ott
    Department of Surgery, Technische Universitaet Muenchen, Ismaningerstr 22, D 81675, Munich, Germany
    J Clin Oncol 24:4692-8. 2006
  3. doi request reprint Molecular imaging of proliferation and glucose utilization: utility for monitoring response and prognosis after neoadjuvant therapy in locally advanced gastric cancer
    Katja Ott
    Department of Surgery, University of Heidelberg, Heidelberg, Germany
    Ann Surg Oncol 18:3316-23. 2011
  4. ncbi request reprint Induction chemotherapy in Barrett cancer: influence on surgical risk and outcome
    Joerg R Siewert
    Department of Surgery, Klinikum rechts der Isar, Technische Universitat Munchen, Munich, Germany
    Ann Surg 246:624-8; discussion 628-31. 2007
  5. doi request reprint DNA repair gene and MTHFR gene polymorphisms as prognostic markers in locally advanced adenocarcinoma of the esophagus or stomach treated with cisplatin and 5-fluorouracil-based neoadjuvant chemotherapy
    Katja Ott
    Department of Surgery, University Hospital Heidelberg, Heidelberg, Germany
    Ann Surg Oncol 18:2688-98. 2011
  6. ncbi request reprint Neoadjuvant chemotherapy with cisplatin, 5-FU, and leucovorin (PLF) in locally advanced gastric cancer: a prospective phase II study
    Katja Ott
    Department of Surgery, Klinikum rechts der Isar der Technischen Universitat Munchen, Ismaninger Str 22, 81675 Munich, Germany
    Gastric Cancer 6:159-67. 2003
  7. ncbi request reprint PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial
    Florian Lordick
    Department of Surgery, Clinic rechts der Isar, Technical University of Munich, Munich, Germany
    Lancet Oncol 8:797-805. 2007
  8. ncbi request reprint Prediction of tumor response by FDG-PET: comparison of the accuracy of single and sequential studies in patients with adenocarcinomas of the esophagogastric junction
    Hinrich A Wieder
    Department of Nuclear Medicine, Klinikum rechts der Isar, Technische Universitaet Muenchen, Ismaningerstrasse 22, Munich, Germany
    Eur J Nucl Med Mol Imaging 34:1925-32. 2007
  9. ncbi request reprint Factors predicting prognosis and recurrence in patients with esophago-gastric adenocarcinoma and histopathological response with less than 10 % residual tumor
    Katja Ott
    Department of Surgery, University Hospital of Heidelberg, Heidelberg, Germany
    Langenbecks Arch Surg 398:239-49. 2013
  10. doi request reprint Early metabolic response evaluation by fluorine-18 fluorodeoxyglucose positron emission tomography allows in vivo testing of chemosensitivity in gastric cancer: long-term results of a prospective study
    Katja Ott
    Department of Surgery, Technische Universitat Munchen, Munich, Germany
    Clin Cancer Res 14:2012-8. 2008

Collaborators

Detail Information

Publications43

  1. ncbi request reprint Prediction of response to preoperative chemotherapy in gastric carcinoma by metabolic imaging: results of a prospective trial
    Katja Ott
    Department of Surgery, Technische Universitä München, Munich, Germany
    J Clin Oncol 21:4604-10. 2003
    ..We prospectively evaluated the predictive value of therapy-induced reduction of tumor glucose use for subsequent response and patient survival in patients with gastric cancer treated by preoperative chemotherapy...
  2. ncbi request reprint Metabolic imaging predicts response, survival, and recurrence in adenocarcinomas of the esophagogastric junction
    Katja Ott
    Department of Surgery, Technische Universitaet Muenchen, Ismaningerstr 22, D 81675, Munich, Germany
    J Clin Oncol 24:4692-8. 2006
    ..The aim of this study was to prospectively validate these findings by using an a priori definition of metabolic response...
  3. doi request reprint Molecular imaging of proliferation and glucose utilization: utility for monitoring response and prognosis after neoadjuvant therapy in locally advanced gastric cancer
    Katja Ott
    Department of Surgery, University of Heidelberg, Heidelberg, Germany
    Ann Surg Oncol 18:3316-23. 2011
    ..In this study we tested whether FLT-positron emission tomography (PET) can improve the predictive potential of molecular imaging for assessing response to neoadjuvant therapy in gastric cancer compared with FDG-PET...
  4. ncbi request reprint Induction chemotherapy in Barrett cancer: influence on surgical risk and outcome
    Joerg R Siewert
    Department of Surgery, Klinikum rechts der Isar, Technische Universitat Munchen, Munich, Germany
    Ann Surg 246:624-8; discussion 628-31. 2007
    ..To study the impact of induction chemotherapy on surgical risk and outcome in locally advanced Barrett cancer...
  5. doi request reprint DNA repair gene and MTHFR gene polymorphisms as prognostic markers in locally advanced adenocarcinoma of the esophagus or stomach treated with cisplatin and 5-fluorouracil-based neoadjuvant chemotherapy
    Katja Ott
    Department of Surgery, University Hospital Heidelberg, Heidelberg, Germany
    Ann Surg Oncol 18:2688-98. 2011
    ..We assessed 12 polymorphisms in 7 DNA repair genes and 2 polymorphisms in the MTHFR gene for association with disease response and prognosis...
  6. ncbi request reprint Neoadjuvant chemotherapy with cisplatin, 5-FU, and leucovorin (PLF) in locally advanced gastric cancer: a prospective phase II study
    Katja Ott
    Department of Surgery, Klinikum rechts der Isar der Technischen Universitat Munchen, Ismaninger Str 22, 81675 Munich, Germany
    Gastric Cancer 6:159-67. 2003
    ..Primary endpoints of the study were the toxicity and the response to chemotherapy. Secondary endpoints were the rate of complete resection, survival, and first site of failure...
  7. ncbi request reprint PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial
    Florian Lordick
    Department of Surgery, Clinic rechts der Isar, Technical University of Munich, Munich, Germany
    Lancet Oncol 8:797-805. 2007
    ..We aimed to assess the feasibility of a PET-response-guided treatment algorithm and its potential effect on prognosis...
  8. ncbi request reprint Prediction of tumor response by FDG-PET: comparison of the accuracy of single and sequential studies in patients with adenocarcinomas of the esophagogastric junction
    Hinrich A Wieder
    Department of Nuclear Medicine, Klinikum rechts der Isar, Technische Universitaet Muenchen, Ismaningerstrasse 22, Munich, Germany
    Eur J Nucl Med Mol Imaging 34:1925-32. 2007
    ..To address this question we studied the time course of changes in tumor FDG-uptake in patients with locally advanced adenocarcinomas of the esophagogastric junction (AEG) treated with preoperative chemotherapy...
  9. ncbi request reprint Factors predicting prognosis and recurrence in patients with esophago-gastric adenocarcinoma and histopathological response with less than 10 % residual tumor
    Katja Ott
    Department of Surgery, University Hospital of Heidelberg, Heidelberg, Germany
    Langenbecks Arch Surg 398:239-49. 2013
    ..The aim of this retrospective exploratory study from two academic centers was to identify predictors of survival and recurrence in histopathologically responding patients...
  10. doi request reprint Early metabolic response evaluation by fluorine-18 fluorodeoxyglucose positron emission tomography allows in vivo testing of chemosensitivity in gastric cancer: long-term results of a prospective study
    Katja Ott
    Department of Surgery, Technische Universitat Munchen, Munich, Germany
    Clin Cancer Res 14:2012-8. 2008
    ..The goal of the study was the definition of biologically different groups of patients prior to or early during induction therapy, with special emphasis on FDG non-avid tumors...
  11. ncbi request reprint Prognostic impact of lymph node involvement and the extent of lymphadenectomy (LAD) in adenocarcinoma of the esophagogastric junction (AEG)
    Leila Sisic
    Department of Surgery, University Hospital Heidelberg, INF 110, 69120, Heidelberg, Germany
    Langenbecks Arch Surg 398:973-81. 2013
    ..We examined the prognostic value of the number of positive LNs, number of LNs removed, and LN ratio (LNR) in order to determine the influence of an adequate LAD on overall survival (OS)...
  12. ncbi request reprint Combined GADD45A and thymidine phosphorylase expression levels predict response and survival of neoadjuvant-treated gastric cancer patients
    Rudolf Napieralski
    Department of Pathology, Technische Universitat Munchen, Munich, Germany
    Clin Cancer Res 11:3025-31. 2005
    ..We evaluated the expression of seven therapy-related genes to predict the clinical outcome of advanced gastric cancer patients treated with a neoadjuvant chemotherapeutic protocol...
  13. doi request reprint The new credo: induction chemotherapy in locally advanced gastric cancer: consequences for surgical strategies
    Katja Ott
    Department of Surgery, University of Heidelberg, Im Neuenheimer Feld 110, Heidelberg, Germany
    Gastric Cancer 11:1-9. 2008
    ....
  14. ncbi request reprint Methylation of tumor-related genes in neoadjuvant-treated gastric cancer: relation to therapy response and clinicopathologic and molecular features
    Rudolf Napieralski
    Department of Pathology, Technische Universitat Munchen, Munich, Germany
    Clin Cancer Res 13:5095-102. 2007
    ..Furthermore, we analyzed the relationship of promoter hypermethylation with microsatellite instability and loss of heterozygosity (LOH) of the tumors...
  15. ncbi request reprint Glutathione-S-transferase P1, T1 and M1 genetic polymorphisms in neoadjuvant-treated locally advanced gastric cancer: GSTM1-present genotype is associated with better prognosis in completely resected patients
    Katja Ott
    Department of Surgery, University Hospital of Heidelberg, Im Neuenheimer Feld 110, 69120, Heidelberg, Germany
    Int J Colorectal Dis 23:773-82. 2008
    ..Therefore, glutathione-S-transferase (GST) polymorphisms were assessed as predictive markers in cisplatinum-based neoadjuvant-treated gastric cancer...
  16. doi request reprint Histone deacetylase (HDAC) 1 and 2 expression and chemotherapy in gastric cancer
    Kathrin Mutze
    Institute of Pathology, Technische Universitat Munchen, Munich, Germany
    Ann Surg Oncol 17:3336-43. 2010
    ..We investigated HDAC1 and -2 expression in gastric carcinomas (GCs) for an association of patient outcome with conventional neoadjuvant chemotherapy. In vitro, HDAC inhibitors were evaluated as alternative treatment options...
  17. doi request reprint (18)F-FDG PET-guided salvage neoadjuvant radiochemotherapy of adenocarcinoma of the esophagogastric junction: the MUNICON II trial
    Christian Meyer Zum Büschenfelde
    3rd Department of Medicine Haematology and Medical Oncology, Klinikum rechts der Isar, Technische Universitat Munchen, Munich, Germany
    J Nucl Med 52:1189-96. 2011
    ..Therefore, we initiated this prospective trial to improve the clinical outcome of metabolic nonresponders using a salvage neoadjuvant radiochemotherapy...
  18. ncbi request reprint Adenocarcinomas of esophagogastric junction: multi-detector row CT to evaluate early response to neoadjuvant chemotherapy
    Ambros J Beer
    Department of Radiology, Technische Universitaet Muenchen, Klinikum rechts der Isar, Ismaninger Str 22, 81675 Munich, Germany
    Radiology 239:472-80. 2006
    ..To prospectively evaluate multi-detector row computed tomography (CT) in the assessment of early response during neoadjuvant chemotherapy for adenocarcinoma of the esophagogastric junction (AEG)...
  19. ncbi request reprint Fluorodeoxyglucose-positron emission tomography in adenocarcinomas of the distal esophagus and cardia
    Katja Ott
    Department of Surgery, Klinikum rechts der Isar, Technical University Munich, Ismaningerstrasse 22, D 81675 Munich, Germany
    World J Surg 27:1035-9. 2003
    ..This finding strengthens the hypothesis that AEG I and AEG II are two different tumor entities...
  20. ncbi request reprint Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy
    Karen Becker
    Institute of Pathology, Klinikum rechts der Isar, Technische Universitat Munchen, Munich, Germany
    Cancer 98:1521-30. 2003
    ..The authors performed the current study to determine which histomorphologic features are correlated with patient prognosis after chemotherapy...
  21. doi request reprint Paclitaxel in the neoadjuvant treatment for adeno carcinoma of the distal esophagus (AEG I). A comparison of two phase II trials with long-term follow-up
    Franz G Bader
    Department of Surgery, University of Schleswig Holstein, Campus Lubeck, Germany
    Onkologie 31:366-72. 2008
    ..We report a comparative analysis of 2 sequential, prospective phase II trials on the efficacy of platinum/leucovorin/5-fluorouracil (PLF) +/- paclitaxel (T-PLF) in the neoadjuvant treatment of adenocarcinoma of the esophagus (AEG I)...
  22. doi request reprint Expression of class I histone deacetylases (HDAC1 and HDAC2) in oesophageal adenocarcinomas: an immunohistochemical study
    Rupert Langer
    Institute of Pathology, Technische Universitat Munchen, Munich, Germany
    J Clin Pathol 63:994-8. 2010
    ..Deregulation of HDACs has been detected in various human malignancies and may also influence response to chemotherapy...
  23. ncbi request reprint The thymidylate synthase tandem repeat promoter polymorphism: A predictor for tumor-related survival in neoadjuvant treated locally advanced gastric cancer
    Katja Ott
    Department of Surgery, Technical University, Munich, Germany
    Int J Cancer 119:2885-94. 2006
    ..93). Patients' survival after CTx was associated with the TS tandem repeat polymorphism. CTx did not improve survival of patients with the 3rpt/3rpt genotype. Thus, a different therapy might be more appropriate for these patients...
  24. ncbi request reprint Comparison of changes in tumor metabolic activity and tumor size during chemotherapy of adenocarcinomas of the esophagogastric junction
    Hinrich A Wieder
    Department of Nuclear Medicine, Klinikum rechts der Isar, Technische Universitat Munchen, Munich, Germany
    J Nucl Med 46:2029-34. 2005
    ..We evaluated the temporal relationship between chemotherapy-induced changes in tumor glucose use and tumor size...
  25. pmc Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia: European Organisation for Research and Treatment of Cancer randomized trial 40954
    Christoph Schuhmacher
    Klinikum rechts der Isar, Chirurgische Klinik der TU München, Ismaningerstr 22, D 81675 Munchen, Germany
    J Clin Oncol 28:5210-8. 2010
    ..We examined the value of purely preoperative chemotherapy in a phase III trial with strict preoperative staging and surgical resection guidelines...
  26. ncbi request reprint Interim endoscopy results during neoadjuvant therapy for gastric cancer correlate with histopathological response and prognosis
    Ulrike Heger
    Department of Surgery, University of Heidelberg, Im Neuenheimer Feld 110, 69120, Heidelberg, Germany
    Gastric Cancer 17:478-88. 2014
    ..Data on interim endoscopic response assessment do not exist. This exploratory prospective study evaluates early endoscopy after 50 % of the chemotherapy as predictor for later response and prognosis...
  27. ncbi request reprint Is preoperative chemotherapy followed by surgery the appropriate treatment for signet ring cell containing adenocarcinomas of the esophagogastric junction and stomach?
    Ulrike Heger
    Department of Surgery, Heidelberg University Hospital, University of Heidelberg, Heidelberg, Germany
    Ann Surg Oncol 21:1739-48. 2014
    ..The aim of our retrospective exploratory study was to evaluate the influence of SRC on prognosis and response in esophagogastric adenocarcinoma treated with neoadjuvant chemotherapy...
  28. pmc A retrospective comparative exploratory study on two Methylentetrahydrofolate Reductase (MTHFR) polymorphisms in esophagogastric cancer: the A1298C MTHFR polymorphism is an independent prognostic factor only in neoadjuvantly treated gastric cancer patient
    Susanne Blank
    Department of Surgery, University Hospital of Heidelberg, Im Neuenheimer Feld 110, Heidelberg 69120, Germany
    BMC Cancer 14:58. 2014
    ..Our aim was to evaluate the prognostic and predictive value of two well characterized constitutional MTHFR gene polymorphisms for primarily resected and neoadjuvantly treated esophagogastric adenocarcinomas...
  29. ncbi request reprint Protein expression profiling in esophageal adenocarcinoma patients indicates association of heat-shock protein 27 expression and chemotherapy response
    Rupert Langer
    Institute of Pathology, Klinikum rechts der Isar, Technische Universitat Munchen, Munich, Germany
    Clin Cancer Res 14:8279-87. 2008
    ....
  30. ncbi request reprint Imaging gastric cancer with PET and the radiotracers 18F-FLT and 18F-FDG: a comparative analysis
    Ken Herrmann
    Department of Nuclear Medicine, Technische Universitat Munchen, Munich, Germany
    J Nucl Med 48:1945-50. 2007
    ..In this pilot study, we evaluated 3'-deoxy-3'-(18)F-fluorothymidine (FLT) PET for the detection of gastric cancer and compared the diagnostic accuracy with that of (18)F-FDG PET...
  31. ncbi request reprint Gastric cancer: surgery in 2011
    Katja Ott
    Department of Surgery, University of Heidelberg, INF 110, 69120 Heidelberg, Germany
    Langenbecks Arch Surg 396:743-58. 2011
    ..Early gastric cancer that is limited to the mucosal layer is the domain of endoscopic resections. As soon as the submucosal layer is invaded, surgical strategies with adequate lymphadenectomy become necessary...
  32. ncbi request reprint Imaging of esophageal and gastric cancer
    Wolfgang A Weber
    Department of Nuclear Medicine, Technische Universitaet Muenchen, Munich, Germany
    Semin Oncol 31:530-41. 2004
    ..Furthermore, quantitative measurements of tumor FDG uptake may predict histopathologic tumor response and patient outcome as early as 2 weeks after initiation of preoperative chemotherapy...
  33. ncbi request reprint Surgical factors influence the outcome after Ivor-Lewis esophagectomy with intrathoracic anastomosis for adenocarcinoma of the esophagogastric junction: a consecutive series of 240 patients at an experienced center
    Katja Ott
    Department of Surgery, University of Heidelberg, Heidelberg, Germany
    Ann Surg Oncol 16:1017-25. 2009
    ..Thus, we evaluated the surgical risk and outcome after an abdominothoracic esophagectomy (Ivor-Lewis) with intrathoracic anastomosis as standard procedure...
  34. ncbi request reprint Chromosomal instability rather than p53 mutation is associated with response to neoadjuvant cisplatin-based chemotherapy in gastric carcinoma
    Katja Ott
    Department of Surgery, Klinikum rechts der Isar, Technische Universitat Munchen, D 81675 Munich, Germany
    Clin Cancer Res 9:2307-15. 2003
    ....
  35. ncbi request reprint FDG PET imaging of locally advanced gastric carcinomas: correlation with endoscopic and histopathological findings
    Alexander Stahl
    Department of Nuclear Medicine, Technische Universitat Munchen, Klinikum rechts der Isar, Ismaninger Strasse 22, 81675 Munchen, Germany
    Eur J Nucl Med Mol Imaging 30:288-95. 2003
    ..This may limit the value of FDG PET for diagnosis and therapy monitoring in patients with gastric carcinomas. Furthermore, the intensity of tumour FDG uptake is not predictive of survival in gastric carcinomas...
  36. ncbi request reprint Are squamous and adenocarcinomas of the esophagus the same disease?
    J Rudiger Siewert
    Department of Surgery, Klinikum rechts der Isar, Technische Universitat, Munchen, Germany
    Semin Radiat Oncol 17:38-44. 2007
    ..We suggest that the two different tumor entities should be analyzed and reported separately to provide comparable results in the future...
  37. pmc The Value of PET Imaging in Patients with Localized Gastroesophageal Cancer
    Katja Ott
    Department of Surgery, University of Heidelberg, Heidelberg, Germany
    Gastrointest Cancer Res 2:287-94. 2008
    ....
  38. ncbi request reprint Current status of neoadjuvant therapy for adenocarcinoma of the distal esophagus
    Johannes Zacherl
    Universitatsklinik fur Chirurgie, Klinische Abteilung für Allgemeinchirurgie, Allgemeines Krankenhaus der Stadt Wien, Wahringer Gurtel 18 20, A 1090 Vienna, Austria
    World J Surg 27:1067-74. 2003
    ..Neoadjuvant treatment of adenocarcinoma of the esophagus, as a consequence, is currently not the standard treatment and should be performed only within controlled clinical trials...
  39. ncbi request reprint Prediction of response to neoadjuvant chemotherapy in carcinomas of the upper gastrointestinal tract
    Heinz Hofler
    Institute of Pathology, Technical University Munich, Germany
    Recent Results Cancer Res 176:33-6. 2007
    ..Our studies point to promising markers with potential use for chemotherapy response prediction of adenocarcinomas of the upper gastrointestinal tract, but prospective studies for validation are necessary...
  40. ncbi request reprint Prediction of response to neoadjuvant chemotherapy in carcinomas of the upper gastrointestinal tract
    Heinz Hofler
    Institute of Pathologyy, Technical University Munchen, Trogerstr 18, 81675 Munchen, Germany
    Adv Exp Med Biol 587:115-20. 2006
    ..Our studies point to promising markers with potential use for chemotherapy response prediction of adenocarcinomas of the upper gastrointestinal tract, but prospective studies for validation are necessary...
  41. ncbi request reprint Comparison of pretherapeutic and posttherapeutic expression levels of chemotherapy-associated genes in adenocarcinomas of the esophagus treated by 5-fluorouracil- and cisplatin-based neoadjuvant chemotherapy
    Rupert Langer
    Institute of Pathology, Klinikum rechts der Isar, Technische Universitat, Munchen, Germany
    Am J Clin Pathol 128:191-7. 2007
    ..Down-regulation of chemotherapy metabolism-associated genes occurs after neoadjuvant chemotherapy and may modulate tumor response to chemotherapy...
  42. ncbi request reprint PET imaging with [11C]methyl- L-methionine for therapy monitoring in patients with rectal cancer
    Hinrich Wieder
    Department of Nuclear Medicine, Technische Universitat Munchen, Ismaningerstrasse 22, Germany
    Eur J Nucl Med Mol Imaging 29:789-96. 2002
    ..In conclusion, primary rectal cancer can be imaged with MET-PET. However, for the studied chemoradiotherapy regimen, MET-PET did not allow an assessment of the response to therapy...
  43. ncbi request reprint The evolving role of catumaxomab in gastric cancer
    Florian Lordick
    University of Heidelberg, National Center for Tumour Diseases, Department of Medical Oncology, Im Neuenheimer Feld 350, 69120 Heidelberg, Germany
    Expert Opin Biol Ther 8:1407-15. 2008
    ..Intraperitoneal administration of catumaxomab in patients with malignant ascites due to epithelial cancer significantly increased puncture-free survival...